IMMUNOMODULATOR, BIOLOGIC, DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Remicade is a prescription medication approved by the Food and Drug Administration (FDA) for the treatment of psoriatic arthritis and for chronic severe plaque psoriasis in people who are candidates for systemic therapy. Remicade may be referred to by its drug name, Infliximab.
Remicade is an immunomodulator, or drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). It is a genetically engineered antibody used by the immune system to identify and neutralize substances. Remicade is believed to work by attaching to tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. Remicade binds to TNF-α and prevents it from signaling the immune system to attack the connective tissues.
How do I take it?
Remicade is administered as an intravenous infusion every four or eight weeks after initial loading doses.
Remicade is available in vial form.
The FDA-approved label for Remicade lists common side effects including headache, cold and flu symptoms, abdominal pain, and infusion reactions.
Rare but serious side effects listed for Remicade can include blood disorders, severe infections, increased risk for certain types of cancer, heart failure, liver failure, lupus-like syndrome, and the development of neurological conditions such as multiple sclerosis.
For answers to frequently asked questions about exposure to Remicade during pregnancy and breastfeeding, visit the experts at MothertoBaby.org.
For more details about this treatment, visit:
Remicade – Janssen